«We look forward to conducting further research through the STARTRK - 2 phase II trial and are hopeful that treatment with entrectinib in patients with a range of advanced or metastatic solid tumors harboring NTRK1 / 2/3, ROS1, or
ALK gene fusions will result in very meaningful benefit.»